
    
      Primary Objective: To determine the efficacy of Gefitinib in NSCLC patient harboring a
      positive EGFR mutation.

      Secondary Objective: To evaluate the subjective response of NSCLC patients harboring a
      positive EGFR mutation who treated with Gefitinib.

      Safety Objective: To evaluate the safety and tolerability of Gefitinib in NSCLC patient
      harboring a positive EGFR mutation.
    
  